MPO and neoplasm: Moreover, a new biologic tripeptide inhibitor of MPO activity, N-acetyl lysyltyrosylcysteine amide (KYC), has been proposed as a treatment during the inflammatory stage in the early stages of tumor development, suggesting the use of MPO inhibitors in cancer prevention [90,91].